Literature DB >> 30192101

Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis.

Irene Bighelli1, Georgia Salanti2, Maximilian Huhn1, Johannes Schneider-Thoma1, Marc Krause1, Cornelia Reitmeir1, Sofia Wallis1, Felicitas Schwermann1, Gabi Pitschel-Walz1, Corrado Barbui3, Toshi A Furukawa4, Stefan Leucht1.   

Abstract

Psychological treatments are increasingly regarded as useful interventions for schizophrenia. However, a comprehensive evaluation of the available evidence is lacking and the benefit of psychological interventions for patients with current positive symptoms is still debated. The present study aimed to evaluate the efficacy, acceptability and tolerability of psychological treatments for positive symptoms of schizophrenia by applying a network meta-analysis approach, that can integrate direct and indirect comparisons. We searched EMBASE, MEDLINE, PsycINFO, PubMed, BIOSIS, Cochrane Library, World Health Organization's International Clinical Trials Registry Platform and ClinicalTrials.gov for randomized controlled trials of psychological treatments for positive symptoms of schizophrenia, published up to January 10, 2018. We included studies on adults with a diagnosis of schizophrenia or a related disorder presenting positive symptoms. The primary outcome was change in positive symptoms measured with validated rating scales. We included 53 randomized controlled trials of seven psychological interventions, for a total of 4,068 participants receiving the psychological treatment as add-on to antipsychotics. On average, patients were moderately ill at baseline. The network meta-analysis showed that cognitive behavioural therapy (40 studies) reduced positive symptoms more than inactive control (standardized mean difference, SMD=-0.29; 95% CI: -0.55 to -0.03), treatment as usual (SMD=-0.30; 95% CI: -0.45 to -0.14) and supportive therapy (SMD=-0.47; 95% CI: -0.91 to -0.03). Cognitive behavioural therapy was associated with a higher dropout rate compared with treatment as usual (risk ratio, RR=0.74; 95% CI: 0.58 to 0.95). Confidence in the estimates ranged from moderate to very low. The other treatments contributed to the network with a lower number of studies. Results were overall consistent in sensitivity analyses controlling for several factors, including the role of researchers' allegiance and blinding of outcome assessor. Cognitive behavior therapy seems to be effective on positive symptoms in moderately ill patients with schizophrenia, with effect sizes in the lower to medium range, depending on the control condition.
© 2018 World Psychiatric Association.

Entities:  

Keywords:  Schizophrenia; cognitive behavioural therapy; network meta-analysis; positive symptoms; psychological interventions

Year:  2018        PMID: 30192101      PMCID: PMC6127754          DOI: 10.1002/wps.20577

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  70 in total

1.  Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials.

Authors:  D Lynch; K R Laws; P J McKenna
Journal:  Psychol Med       Date:  2009-05-29       Impact factor: 7.723

2.  Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial.

Authors:  Lucia R Valmaggia; Mark van der Gaag; Nicholas Tarrier; Marieke Pijnenborg; Cees J Slooff
Journal:  Br J Psychiatry       Date:  2005-04       Impact factor: 9.319

3.  Checking consistency in mixed treatment comparison meta-analysis.

Authors:  S Dias; N J Welton; D M Caldwell; A E Ades
Journal:  Stat Med       Date:  2010-03-30       Impact factor: 2.373

4.  Randomized controlled trial of an internet cognitive behavioral skills-based program for auditory hallucinations in persons with psychosis.

Authors:  Jennifer D Gottlieb; Vasudha Gidugu; Mihoko Maru; Miriam C Tepper; Matthew J Davis; Jennifer Greenwold; Ruth A Barron; Brian P Chiko; Kim T Mueser
Journal:  Psychiatr Rehabil J       Date:  2017-05-18

5.  North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: outcomes at 6 and 12 months.

Authors:  M Startup; M C Jackson; S Bendix
Journal:  Psychol Med       Date:  2004-04       Impact factor: 7.723

6.  Cognitive--behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial.

Authors:  Philippa A Garety; David G Fowler; Daniel Freeman; Paul Bebbington; Graham Dunn; Elizabeth Kuipers
Journal:  Br J Psychiatry       Date:  2008-06       Impact factor: 9.319

7.  Metacognitive training for delusions (MCTd): effectiveness on data-gathering and belief flexibility in a Chinese sample.

Authors:  Suzanne Ho-Wai So; Arthur P Chan; Catherine Shiu-Yin Chong; Melissa Hiu-Mei Wong; William Tak-Lam Lo; Dicky Wai-Sau Chung; Sandra S Chan
Journal:  Front Psychol       Date:  2015-06-15

8.  Cognitive behaviour therapy to prevent harmful compliance with command hallucinations (COMMAND): a randomised controlled trial.

Authors:  Max Birchwood; Maria Michail; Alan Meaden; Nicholas Tarrier; Shon Lewis; Til Wykes; Linda Davies; Graham Dunn; Emmanuelle Peters
Journal:  Lancet Psychiatry       Date:  2014-06-04       Impact factor: 27.083

9.  Ranking treatments in frequentist network meta-analysis works without resampling methods.

Authors:  Gerta Rücker; Guido Schwarzer
Journal:  BMC Med Res Methodol       Date:  2015-07-31       Impact factor: 4.615

10.  Effects of cognitive behaviour therapy for worry on persecutory delusions in patients with psychosis (WIT): a parallel, single-blind, randomised controlled trial with a mediation analysis.

Authors:  Daniel Freeman; Graham Dunn; Helen Startup; Katherine Pugh; Jacinta Cordwell; Helen Mander; Emma Černis; Gail Wingham; Katherine Shirvell; David Kingdon
Journal:  Lancet Psychiatry       Date:  2015-03-31       Impact factor: 27.083

View more
  25 in total

1.  The controversy about cognitive behavioural therapy for schizophrenia.

Authors:  Peter McKenna; Stefan Leucht; Sammy Jauhar; Keith Laws; Irene Bighelli
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

2.  Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics.

Authors:  Irene Bighelli; Claudia Leucht; Maximilian Huhn; Cornelia Reitmeir; Felicitas Schwermann; Sofia Wallis; John M Davis; Stefan Leucht
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

3.  The clinical characterization of the patient with primary psychosis aimed at personalization of management.

Authors:  Mario Maj; Jim van Os; Marc De Hert; Wolfgang Gaebel; Silvana Galderisi; Michael F Green; Sinan Guloksuz; Philip D Harvey; Peter B Jones; Dolores Malaspina; Patrick McGorry; Jouko Miettunen; Robin M Murray; Keith H Nuechterlein; Victor Peralta; Graham Thornicroft; Ruud van Winkel; Joseph Ventura
Journal:  World Psychiatry       Date:  2021-02       Impact factor: 49.548

4.  Effect of a Nurse-Led Preventive Psychological Intervention on Symptoms of Posttraumatic Stress Disorder Among Critically Ill Patients: A Randomized Clinical Trial.

Authors:  Dorothy M Wade; Paul R Mouncey; Alvin Richards-Belle; Jerome Wulff; David A Harrison; M Zia Sadique; Richard D Grieve; Lydia M Emerson; Alexina J Mason; David Aaronovitch; Nicole Als; Chris R Brewin; Sheila E Harvey; David C J Howell; Nicholas Hudson; Monty G Mythen; Deborah Smyth; John Weinman; John Welch; Chris Whitman; Kathryn M Rowan
Journal:  JAMA       Date:  2019-02-19       Impact factor: 56.272

Review 5.  Cognitive behavioural therapy (group) for schizophrenia.

Authors:  Giuseppe Guaiana; Massimiliano Abbatecola; Ghazaleh Aali; Federica Tarantino; Ikenna D Ebuenyi; Valeria Lucarini; Wei Li; Caidi Zhang; Antonio Pinto
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

6.  Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence.

Authors:  Marco Solmi; Giovanni Croatto; Giada Piva; Stella Rosson; Paolo Fusar-Poli; Jose M Rubio; Andre F Carvalho; Eduard Vieta; Celso Arango; Nicole R DeTore; Elizabeth S Eberlin; Kim T Mueser; Christoph U Correll
Journal:  Mol Psychiatry       Date:  2022-08-23       Impact factor: 13.437

7.  Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia.

Authors:  Stefan Leucht; Johannes Hamann; Spyridon Siafis; Nicola Bursch; Katharina Müller; Lisa Schmid; Florian Schuster; Jakob Waibel; Tri Huynh; Florian Matthes; Alessandro Rodolico; Peter Brieger; Markus Bühner; Stephan Heres
Journal:  BMC Psychiatry       Date:  2022-06-17       Impact factor: 4.144

8.  Exercise as Medicine for Mental and Substance Use Disorders: A Meta-review of the Benefits for Neuropsychiatric and Cognitive Outcomes.

Authors:  Garcia Ashdown-Franks; Joseph Firth; Rebekah Carney; Andre F Carvalho; Mats Hallgren; Ai Koyanagi; Simon Rosenbaum; Felipe B Schuch; Lee Smith; Marco Solmi; Davy Vancampfort; Brendon Stubbs
Journal:  Sports Med       Date:  2020-01       Impact factor: 11.136

9.  Improving treatments for psychotic disorders: beyond cognitive behaviour therapy for psychosis.

Authors:  B Nelson; L Torregrossa; A Thompson; L A Sass; S Park; J A Hartmann; P D McGorry; M Alvarez-Jimenez
Journal:  Psychosis       Date:  2020-06-19

10.  Comparison of a theoretically driven cognitive therapy (the Feeling Safe Programme) with befriending for the treatment of persistent persecutory delusions: a parallel, single-blind, randomised controlled trial.

Authors:  Daniel Freeman; Richard Emsley; Rowan Diamond; Nicola Collett; Emily Bold; Eleanor Chadwick; Louise Isham; Jessica C Bird; Danielle Edwards; David Kingdon; Ray Fitzpatrick; Thomas Kabir; Felicity Waite
Journal:  Lancet Psychiatry       Date:  2021-07-08       Impact factor: 77.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.